APO Research
Talk to an analyst

APO RESEARCH · REPORT

Herceptin Biosimilar

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Herceptin Biosimilar Industry Growth and Trends Forecast to 2032

22 December 2025108 pages

Choose your research edition.

Industry ResearchHerceptin Biosimilar Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Herceptin Biosimilar Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Herceptin Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Herceptin Biosimilar Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Herceptin Biosimilar Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Herceptin Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Herceptin Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Herceptin Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Herceptin Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Herceptin Biosimilar include Mylan, Roche, Amgen, The Instituto Vital Brazil, Mabion, Genor Biopharma, Gedeon Richter, Celltrion and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Herceptin Biosimilar market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Herceptin Biosimilar market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Herceptin Biosimilar market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Herceptin Biosimilar.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Herceptin Biosimilar market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Herceptin Biosimilar Market by Company

Mylan

Roche

Amgen

The Instituto Vital Brazil

Mabion

Genor Biopharma

Gedeon Richter

Celltrion

Biocon

AryoGen Biopharma

Herceptin Biosimilar Segment by Type

Leukemia

Colorectal Cancer

Lymphoma

Breast Cancer

Other

Herceptin Biosimilar Segment by Application

Hospital & Clinics

Oncology Centers

Other

Herceptin Biosimilar Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herceptin Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Herceptin Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herceptin Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Herceptin Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Herceptin Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Leukemia Table 2. Major Company of Colorectal Cancer Table 3. Major Company of Lymphoma Table 4. Major Company of Breast Cancer Table 5. Major Company of Other Table 6. Global Herceptin Biosimilar Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 8. Global Herceptin Biosimilar Sales Market Share in Volume by Type (2021-2026) Table 9. Global Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 10. Global Herceptin Biosimilar Sales Market Share in Value by Type (2021-2026) Table 11. Global Herceptin Biosimilar Price by Type (2021-2026) & (US$/unit) Table 12. Global Herceptin Biosimilar Sales by Type (2027-2032) & (k units) Table 13. Global Herceptin Biosimilar Sales Market Share in Volume by Type (2027-2032) Table 14. Global Herceptin Biosimilar Sales by Type (2027-2032) & (US$ Million) Table 15. Global Herceptin Biosimilar Sales Market Share in Value by Type (2027-2032) Table 16. Global Herceptin Biosimilar Price by Type (2027-2032) & (US$/unit) Table 17. North America Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 18. North America Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 20. Europe Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 24. Latin America Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Herceptin Biosimilar Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Herceptin Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 27. Herceptin Biosimilar Industry Trends Table 28. Herceptin Biosimilar Industry Drivers Table 29. Herceptin Biosimilar Industry Opportunities and Challenges Table 30. Herceptin Biosimilar Industry Restraints Table 31. Global Herceptin Biosimilar Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Herceptin Biosimilar Revenue Market Share by Company (2021-2026) Table 33. Global Herceptin Biosimilar Sales by Company (2021-2026) & (k units) Table 34. Global Herceptin Biosimilar Sales Share by Company (2021-2026) Table 35. Global Herceptin Biosimilar Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Herceptin Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Herceptin Biosimilar Major Company Production Sites and Headquarters Table 38. Global Herceptin Biosimilar Company, Product Type & Application Table 39. Global Herceptin Biosimilar Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Herceptin Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Herceptin Biosimilar Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Herceptin Biosimilar Sales by Region (2021-2026) & (k units) Table 44. Global Herceptin Biosimilar Sales Market Share in Volume by Region (2021-2026) Table 45. Global Herceptin Biosimilar Sales by Region (2021-2026) & (US$ Million) Table 46. Global Herceptin Biosimilar Sales Market Share in Value by Region (2021-2026) Table 47. Global Herceptin Biosimilar Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Herceptin Biosimilar Sales by Region (2027-2032) & (k units) Table 49. Global Herceptin Biosimilar Sales Market Share in Volume by Region (2027-2032) Table 50. Global Herceptin Biosimilar Sales by Region (2027-2032) & (US$ Million) Table 51. Global Herceptin Biosimilar Sales Market Share in Value by Region (2027-2032) Table 52. Global Herceptin Biosimilar Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Herceptin Biosimilar Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 55. Global Herceptin Biosimilar Sales Market Share in Volume by Application (2021-2026) Table 56. Global Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 57. Global Herceptin Biosimilar Sales Market Share in Value by Application (2021-2026) Table 58. Global Herceptin Biosimilar Price by Application (2021-2026) & (US$/unit) Table 59. Global Herceptin Biosimilar Sales by Application (2027-2032) & (k units) Table 60. Global Herceptin Biosimilar Sales Market Share in Volume by Application (2027-2032) Table 61. Global Herceptin Biosimilar Sales by Application (2027-2032) & (US$ Million) Table 62. Global Herceptin Biosimilar Sales Market Share in Value by Application (2027-2032) Table 63. Global Herceptin Biosimilar Price by Application (2027-2032) & (US$/unit) Table 64. North America Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 65. North America Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 67. Europe Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 71. Latin America Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Herceptin Biosimilar Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Herceptin Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 74. Mylan Company Information Table 75. Mylan Business Overview Table 76. Mylan Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Mylan Herceptin Biosimilar Product Portfolio Table 78. Mylan Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Roche Herceptin Biosimilar Product Portfolio Table 83. Roche Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Amgen Herceptin Biosimilar Product Portfolio Table 88. Amgen Recent Development Table 89. The Instituto Vital Brazil Company Information Table 90. The Instituto Vital Brazil Business Overview Table 91. The Instituto Vital Brazil Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. The Instituto Vital Brazil Herceptin Biosimilar Product Portfolio Table 93. The Instituto Vital Brazil Recent Development Table 94. Mabion Company Information Table 95. Mabion Business Overview Table 96. Mabion Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Mabion Herceptin Biosimilar Product Portfolio Table 98. Mabion Recent Development Table 99. Genor Biopharma Company Information Table 100. Genor Biopharma Business Overview Table 101. Genor Biopharma Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Genor Biopharma Herceptin Biosimilar Product Portfolio Table 103. Genor Biopharma Recent Development Table 104. Gedeon Richter Company Information Table 105. Gedeon Richter Business Overview Table 106. Gedeon Richter Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Gedeon Richter Herceptin Biosimilar Product Portfolio Table 108. Gedeon Richter Recent Development Table 109. Celltrion Company Information Table 110. Celltrion Business Overview Table 111. Celltrion Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Celltrion Herceptin Biosimilar Product Portfolio Table 113. Celltrion Recent Development Table 114. Biocon Company Information Table 115. Biocon Business Overview Table 116. Biocon Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Biocon Herceptin Biosimilar Product Portfolio Table 118. Biocon Recent Development Table 119. AryoGen Biopharma Company Information Table 120. AryoGen Biopharma Business Overview Table 121. AryoGen Biopharma Herceptin Biosimilar Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. AryoGen Biopharma Herceptin Biosimilar Product Portfolio Table 123. AryoGen Biopharma Recent Development Table 124. North America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 125. North America Herceptin Biosimilar Sales by Country (2021-2026) & (k units) Table 126. North America Herceptin Biosimilar Sales Market Share by Country (2021-2026) Table 127. North America Herceptin Biosimilar Sales Forecast by Country (2027-2032) & (k units) Table 128. North America Herceptin Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 129. North America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. North America Herceptin Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 131. North America Herceptin Biosimilar Market Share by Country (2021-2026) Table 132. North America Herceptin Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. North America Herceptin Biosimilar Market Share Forecast by Country (2027-2032) Table 134. Europe Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. Europe Herceptin Biosimilar Sales by Country (2021-2026) & (k units) Table 136. Europe Herceptin Biosimilar Sales Market Share by Country (2021-2026) Table 137. Europe Herceptin Biosimilar Sales Forecast by Country (2027-2032) & (k units) Table 138. Europe Herceptin Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 139. Europe Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Europe Herceptin Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 141. Europe Herceptin Biosimilar Market Share by Country (2021-2026) Table 142. Europe Herceptin Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Europe Herceptin Biosimilar Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Herceptin Biosimilar Sales by Country (2021-2026) & (k units) Table 146. Asia-Pacific Herceptin Biosimilar Sales Market Share by Country (2021-2026) Table 147. Asia-Pacific Herceptin Biosimilar Sales Forecast by Country (2027-2032) & (k units) Table 148. Asia-Pacific Herceptin Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 149. Asia-Pacific Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Asia-Pacific Herceptin Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 151. Asia-Pacific Herceptin Biosimilar Market Share by Country (2021-2026) Table 152. Asia-Pacific Herceptin Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Asia-Pacific Herceptin Biosimilar Market Share Forecast by Country (2027-2032) Table 154. Latin America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 155. Latin America Herceptin Biosimilar Sales by Country (2021-2026) & (k units) Table 156. Latin America Herceptin Biosimilar Sales Market Share by Country (2021-2026) Table 157. Latin America Herceptin Biosimilar Sales Forecast by Country (2027-2032) & (k units) Table 158. Latin America Herceptin Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 159. Latin America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Latin America Herceptin Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 161. Latin America Herceptin Biosimilar Market Share by Country (2021-2026) Table 162. Latin America Herceptin Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Latin America Herceptin Biosimilar Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Herceptin Biosimilar Sales by Country (2021-2026) & (k units) Table 166. Middle East and Africa Herceptin Biosimilar Sales Market Share by Country (2021-2026) Table 167. Middle East and Africa Herceptin Biosimilar Sales Forecast by Country (2027-2032) & (k units) Table 168. Middle East and Africa Herceptin Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 169. Middle East and Africa Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Middle East and Africa Herceptin Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Herceptin Biosimilar Market Share by Country (2021-2026) Table 172. Middle East and Africa Herceptin Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Middle East and Africa Herceptin Biosimilar Market Share Forecast by Country (2027-2032) Table 174. Key Raw Materials Table 175. Raw Materials Key Suppliers Table 176. Herceptin Biosimilar Distributors List Table 177. Herceptin Biosimilar Customers List Table 178. Research Programs/Design for This Report Table 179. Authors List of This Report Table 180. Secondary Sources Table 181. Primary Sources List of Figures Figure 1. Herceptin Biosimilar Image Figure 2. Global Herceptin Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Herceptin Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Herceptin Biosimilar Sales (2021-2032) & (k units) Figure 5. Leukemia Image Figure 6. Global Leukemia Sales YoY Growth (2021-2032) & (k units) Figure 7. Colorectal Cancer Image Figure 8. Global Colorectal Cancer Sales YoY Growth (2021-2032) & (k units) Figure 9. Lymphoma Image Figure 10. Global Lymphoma Sales YoY Growth (2021-2032) & (k units) Figure 11. Breast Cancer Image Figure 12. Global Breast Cancer Sales YoY Growth (2021-2032) & (k units) Figure 13. Other Image Figure 14. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Herceptin Biosimilar Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Herceptin Biosimilar Market Share by Type 2025 VS 2032 Figure 17. North America Herceptin Biosimilar Sales Market Share in Volume by Type in 2025 Figure 18. North America Herceptin Biosimilar Sales Market Share in Value by Type in 2025 Figure 19. Europe Herceptin Biosimilar Sales Market Share in Volume by Type in 2025 Figure 20. Europe Herceptin Biosimilar Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Herceptin Biosimilar Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Herceptin Biosimilar Sales Market Share in Value by Type in 2025 Figure 23. Latin America Herceptin Biosimilar Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Herceptin Biosimilar Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Herceptin Biosimilar Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Herceptin Biosimilar Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Herceptin Biosimilar Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital & Clinics Image Figure 30. Global Hospital & Clinics Sales YoY Growth (2021-2032) & (k units) Figure 31. Oncology Centers Image Figure 32. Global Oncology Centers Sales YoY Growth (2021-2032) & (k units) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Herceptin Biosimilar Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Herceptin Biosimilar Market Share by Application 2025 VS 2032 Figure 37. North America Herceptin Biosimilar Sales Market Share in Volume by Application in 2025 Figure 38. North America Herceptin Biosimilar Sales Market Share in Value by Application in 2025 Figure 39. Europe Herceptin Biosimilar Sales Market Share in Volume by Application in 2025 Figure 40. Europe Herceptin Biosimilar Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Herceptin Biosimilar Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Herceptin Biosimilar Sales Market Share in Value by Application in 2025 Figure 43. Latin America Herceptin Biosimilar Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Herceptin Biosimilar Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Herceptin Biosimilar Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Herceptin Biosimilar Sales Market Share in Value by Application in 2025 Figure 47. North America Herceptin Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Herceptin Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Herceptin Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Herceptin Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Herceptin Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Herceptin Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Herceptin Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Herceptin Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Herceptin Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Herceptin Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Herceptin Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Herceptin Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Herceptin Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Herceptin Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Herceptin Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Herceptin Biosimilar Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Herceptin Biosimilar Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Leukemia
  • Colorectal Cancer
  • Lymphoma
  • Breast Cancer
  • Other
Applications
  • Hospital & Clinics
  • Oncology Centers
  • Other
Companies covered
  • Mylan
  • Roche
  • Amgen
  • The Instituto Vital Brazil
  • Mabion
  • Genor Biopharma
  • Gedeon Richter
  • Celltrion
  • Biocon
  • AryoGen Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Herceptin Biosimilar Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Herceptin Biosimilar Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Herceptin Biosimilar Market by Type
  6. 1.3.1 Leukemia
  7. 1.3.2 Colorectal Cancer
  8. 1.3.3 Lymphoma
  9. 1.3.4 Breast Cancer
  10. 1.3.5 Other
  11. 1.4 Global Herceptin Biosimilar Market Size by Type
  12. 1.4.1 Global Herceptin Biosimilar Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Herceptin Biosimilar Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Herceptin Biosimilar Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Herceptin Biosimilar Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Herceptin Biosimilar Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Herceptin Biosimilar Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Herceptin Biosimilar Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Herceptin Biosimilar Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Herceptin Biosimilar Industry Trends
  2. 2.2 Herceptin Biosimilar Industry Drivers
  3. 2.3 Herceptin Biosimilar Industry Opportunities and Challenges
  4. 2.4 Herceptin Biosimilar Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Herceptin Biosimilar Revenue (2021-2026)
  2. 3.2 Global Top Players by Herceptin Biosimilar Sales (2021-2026)
  3. 3.3 Global Top Players by Herceptin Biosimilar Price (2021-2026)
  4. 3.4 Global Herceptin Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Herceptin Biosimilar Major Company Production Sites & Headquarters
  6. 3.6 Global Herceptin Biosimilar Company, Product Type & Application
  7. 3.7 Global Herceptin Biosimilar Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Herceptin Biosimilar Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Herceptin Biosimilar Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Herceptin Biosimilar Tier 1, Tier 2, and Tier 3
4 Herceptin Biosimilar Regional Status and Outlook
  1. 4.1 Global Herceptin Biosimilar Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Herceptin Biosimilar Historic Market Size by Region
  3. 4.2.1 Global Herceptin Biosimilar Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Herceptin Biosimilar Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Herceptin Biosimilar Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Herceptin Biosimilar Forecasted Market Size by Region
  7. 4.3.1 Global Herceptin Biosimilar Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Herceptin Biosimilar Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Herceptin Biosimilar Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Herceptin Biosimilar by Application
  1. 5.1 Herceptin Biosimilar Market by Application
  2. 5.1.1 Hospital & Clinics
  3. 5.1.2 Oncology Centers
  4. 5.1.3 Other
  5. 5.2 Global Herceptin Biosimilar Market Size by Application
  6. 5.2.1 Global Herceptin Biosimilar Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Herceptin Biosimilar Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Herceptin Biosimilar Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Herceptin Biosimilar Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Herceptin Biosimilar Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Herceptin Biosimilar Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Herceptin Biosimilar Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Herceptin Biosimilar Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Mylan
  2. 6.1.1 Mylan Company Information
  3. 6.1.2 Mylan Business Overview
  4. 6.1.3 Mylan Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Mylan Herceptin Biosimilar Product Portfolio
  6. 6.1.5 Mylan Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Roche Herceptin Biosimilar Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Amgen
  14. 6.3.1 Amgen Company Information
  15. 6.3.2 Amgen Business Overview
  16. 6.3.3 Amgen Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Amgen Herceptin Biosimilar Product Portfolio
  18. 6.3.5 Amgen Recent Developments
  19. 6.4 The Instituto Vital Brazil
  20. 6.4.1 The Instituto Vital Brazil Company Information
  21. 6.4.2 The Instituto Vital Brazil Business Overview
  22. 6.4.3 The Instituto Vital Brazil Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 The Instituto Vital Brazil Herceptin Biosimilar Product Portfolio
  24. 6.4.5 The Instituto Vital Brazil Recent Developments
  25. 6.5 Mabion
  26. 6.5.1 Mabion Company Information
  27. 6.5.2 Mabion Business Overview
  28. 6.5.3 Mabion Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mabion Herceptin Biosimilar Product Portfolio
  30. 6.5.5 Mabion Recent Developments
  31. 6.6 Genor Biopharma
  32. 6.6.1 Genor Biopharma Company Information
  33. 6.6.2 Genor Biopharma Business Overview
  34. 6.6.3 Genor Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Genor Biopharma Herceptin Biosimilar Product Portfolio
  36. 6.6.5 Genor Biopharma Recent Developments
  37. 6.7 Gedeon Richter
  38. 6.7.1 Gedeon Richter Company Information
  39. 6.7.2 Gedeon Richter Business Overview
  40. 6.7.3 Gedeon Richter Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Gedeon Richter Herceptin Biosimilar Product Portfolio
  42. 6.7.5 Gedeon Richter Recent Developments
  43. 6.8 Celltrion
  44. 6.8.1 Celltrion Company Information
  45. 6.8.2 Celltrion Business Overview
  46. 6.8.3 Celltrion Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Celltrion Herceptin Biosimilar Product Portfolio
  48. 6.8.5 Celltrion Recent Developments
  49. 6.9 Biocon
  50. 6.9.1 Biocon Company Information
  51. 6.9.2 Biocon Business Overview
  52. 6.9.3 Biocon Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Biocon Herceptin Biosimilar Product Portfolio
  54. 6.9.5 Biocon Recent Developments
  55. 6.10 AryoGen Biopharma
  56. 6.10.1 AryoGen Biopharma Company Information
  57. 6.10.2 AryoGen Biopharma Business Overview
  58. 6.10.3 AryoGen Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AryoGen Biopharma Herceptin Biosimilar Product Portfolio
  60. 6.10.5 AryoGen Biopharma Recent Developments
7 North America by Country
  1. 7.1 North America Herceptin Biosimilar Sales by Country
  2. 7.1.1 North America Herceptin Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Herceptin Biosimilar Sales by Country (2021-2026)
  4. 7.1.3 North America Herceptin Biosimilar Sales Forecast by Country (2027-2032)
  5. 7.2 North America Herceptin Biosimilar Market Size by Country
  6. 7.2.1 North America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Herceptin Biosimilar Market Size by Country (2021-2026)
  8. 7.2.3 North America Herceptin Biosimilar Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Herceptin Biosimilar Sales by Country
  2. 8.1.1 Europe Herceptin Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Herceptin Biosimilar Sales by Country (2021-2026)
  4. 8.1.3 Europe Herceptin Biosimilar Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Herceptin Biosimilar Market Size by Country
  6. 8.2.1 Europe Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Herceptin Biosimilar Market Size by Country (2021-2026)
  8. 8.2.3 Europe Herceptin Biosimilar Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Herceptin Biosimilar Sales by Country
  2. 9.1.1 Asia-Pacific Herceptin Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Herceptin Biosimilar Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Herceptin Biosimilar Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Herceptin Biosimilar Market Size by Country
  6. 9.2.1 Asia-Pacific Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Herceptin Biosimilar Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Herceptin Biosimilar Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Herceptin Biosimilar Sales by Country
  2. 10.1.1 South America Herceptin Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Herceptin Biosimilar Sales by Country (2021-2026)
  4. 10.1.3 South America Herceptin Biosimilar Sales Forecast by Country (2027-2032)
  5. 10.2 South America Herceptin Biosimilar Market Size by Country
  6. 10.2.1 South America Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Herceptin Biosimilar Market Size by Country (2021-2026)
  8. 10.2.3 South America Herceptin Biosimilar Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Herceptin Biosimilar Sales by Country
  2. 11.1.1 Middle East and Africa Herceptin Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Herceptin Biosimilar Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Herceptin Biosimilar Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Herceptin Biosimilar Market Size by Country
  6. 11.2.1 Middle East and Africa Herceptin Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Herceptin Biosimilar Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Herceptin Biosimilar Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Herceptin Biosimilar Value Chain Analysis
  2. 12.1.1 Herceptin Biosimilar Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Herceptin Biosimilar Production Mode & Process
  7. 12.2 Herceptin Biosimilar Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Herceptin Biosimilar Distributors
  10. 12.2.3 Herceptin Biosimilar Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst